Nuvectis Pharma, Inc. 8-K

What Happened

• Nuvectis Pharma, Inc. (NVCT) announced on June 29, 2026 that it entered into an underwriting agreement with Cantor Fitzgerald & Co. to sell 5,000,000 shares of common stock in a firm‑commitment public offering at $20.00 per share. The underwriters have a 30‑day option to buy up to an additional 750,000 shares. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions. The company issued press releases on June 29, 2026 announcing the launch and pricing of the offering.

Key Details

• Shares offered: 5,000,000 firm shares at $20.00 per share.
• Overallotment option: up to 750,000 additional shares, exercisable for 30 days.
• Expected net proceeds: approximately $93 million (or approximately $107 million if the option is exercised), after underwriting discounts, commissions and estimated expenses.
• Registration and counsel: Offering made under the company’s effective Form S-3 shelf (File No. 333-293459); Alston & Bird LLP delivered a legal opinion on the validity of the shares.

Why It Matters

• The offering will raise substantial capital (roughly $93M–$107M) that the company can use for operations, development programs, or other corporate purposes, affecting the company’s cash position and runway.
• Issuing new shares will increase the number of shares outstanding, which can dilute existing shareholders’ ownership percentage; the filing does not state current share count or dilution percentage.
• The agreement is underwritten (firm commitment) by Cantor Fitzgerald, which generally means the company will receive the agreed proceeds at closing (subject to adjustments), and the underwriters assume resale risk.